$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Opko Health’s Revenue by Product Category, comprising of pharmaceutical product category, reported on a quarterly basis from 2016 onwards.
The industry in which Opko Health operates is highly competitive and requires continuous extensive research and technological innovations. Strong emphasis is placed on the proprietary products, technologies advance rapidly, and the competition becomes intense. The company currently has one commercial-stage product and several technologies and products under various different stages of completion. It includes products like Rayaldee, Oxyntomodulin, SARM, Somatrogon, Biologics, APIs, an early stage Biologics pipeline, Factor VIIa-CTP, Oligonucleotide Therapeutics, and some other commercial operations.
|Product Category||Q1 2020||Q2 2020||Q3 2020||Q4 2020||Q1 2021||Q2 2021||Q3 2021||Q4 2021|
(All figures in millions, except percentages)
Opko health’s primary product category is pharmaceuticals. The total revenue from this category increased from $27.95 million in Q4 2020 to $35.28 million in Q4 2021, marking a growth of approximately 26% in revenue on a year-on-year basis. On the other hand, the revenue fell by $1.6 million on a quarterly basis, from $36.88 million in Q3 2021 to $35.28 million in Q4 2021, leading to a 4.3% fall in revenue in the latest quarter. Overall, the revenue grew by around 75% from 2016 to 2021.
In 2020, the revenue from the pharmaceuticals product category has been decreasing continuously. It fell from $33.95 million in Q1 2020 to $29.36 million in Q2 2020, marking a decline of 13.52%. Further, it decreased by 2.24%, from $29.36 million in Q2 2020 to $28.7 million in Q3 2020. This decline continued, as the revenue fell from $28.7 million in Q3 2020 to $27.95 million in Q4 2020, falling by 2.6%.
In 2021, the revenue was rising during the first 3 quarters, however it fell in the latest quarter of Q4 2021. Between Q4 2020 and Q1 2021, the revenue increased by 11.16%, from $27.95 million to $31.07 million. Further, it rose from $31.07 million in Q1 2021 to $35.66 million in Q2 2021, marking an increment of 14.77%. It then increased to $36.88 million in Q3 2021, making a rise of 3.42%, as compared to $35.66 million in Q2 2021. However, the revenue declined from $36.88 million in Q3 2021 to $35.28 million in Q4 2021, making a decline of 4.3% on a quarter-on-quarter basis.
Opko Health was incorporated in Delaware in 1991 with its principal executive office located in Miami. It operates in Spain, Chile, Mexico, and Ireland. The company’s commercial and global supply chain holding company is located in Ireland. It also owns API manufacturers in Israel which are expected to facilitate the development of various molecules and compounds for its proprietary products. The company’s common stock trades under the ticker “OPK” on NASDAQ (National Association of Securities Dealers Automated Quotations).
Opko Health Inc is a diversified healthcare company that aims to be the global industry leader in the rapidly growing medical markets. It consists of mainly two reportable segments-diagnostics and pharmaceuticals. Its diagnostic business includes BioReference Laboratories, which is one of the nation’s largest full-service laboratories. It provides testing services and drives growth and leverages new products in metropolitan cities like New York, Texas, Florida, and other states as well. Laboratories offer clinical diagnostics including hematology, serology, toxicology, Covid-19 testing as well as other tissue analysis. The company is one of the largest providers of Covid-19 screening tests with a capacity of 100,000 PCR tests a day.
The company also features Rayaldee which is an FDA-approved treatment for SHPT in adults. It also has a pipeline of products in different developmental stages including Somatrogon, which is a leading growth hormone injection produced in partnership with Pfizer Inc. Somatrogon is used under the name NGENLA in the European Union for the treatment of children suffering from growth disturbance.
Did you like Opko Health’s Revenue by Product Category statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.